Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX3397 in Recurrent Glioblastoma
NCT01349036Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2011
- Primary completion
- Nov 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pexidartinib in glioblastoma (GBM), sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2011; status: terminated.
02
Drugs
pexidartinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01349036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349036.